You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Respiratory products

Please find a list of our respiratory products below.

▼These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol inhalation powder)

Prescribing Information

Trelegy Ellipta (92/55/22 micrograms inhalation powder) is a combination of inhaled corticosteroid, long-acting muscarinic receptor antagonist and long-acting beta2-adrenergic agonist (ICS/LAMA/LABA) and is indicated for maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA or a combination of a LAMA and a LABA. 

Anoro Ellipta (umeclidinium / vilanterol inhalation powder)

Prescribing information

Anoro Ellipta (55 micrograms/22 micrograms inhalation powder) is a long-acting muscarinic receptor antagonist/long-acting beta2-adrenergic agonist (LAMA/LABA) and is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Incruse Ellipta (umeclidinium inhalation powder)

Prescribing information

Incruse Ellipta (55 micrograms inhalation powder) is a long acting muscarinic receptor antagonist and is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.

Relvar Ellipta (fluticasone furoate/vilanterol inhalation powder)

Prescribing information

Asthma

Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists. 
  • patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.

COPD

Relvar Ellipta (92/22mcg inhalation powder) is indicated for the symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy.

Nucala (mepolizumab)

Prescribing information

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.
The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in pre-filled pen, pre-filled syringe or as a lyophilised powder.
The pre-filled formulations are not indicated in 6-11 year olds.

Seretide 50/100, 50/250, 50/500 Diskus

Asthma

Seretide is indicated in the regular treatment of asthma where use of a combination product (long- acting β2 agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist

or

  • patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist

Note: Seretide 50 microgram /100 microgram strength is not appropriate in adults and children with severe asthma.

Seretide 500/50 Diskus

Chronic Obstructive Pulmonary Disease (COPD)

Seretide is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

Seretide 25/50, 25/125, 25/250 Evohaler

Asthma

Seretide is indicated in the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short- acting β2 agonist

or

  • patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.